配用电
Search documents
三星医疗(601567):2025三季报点评:国内盈利承压,海外配电成长空间广阔
Soochow Securities· 2025-11-03 14:51
Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - Domestic profitability is under pressure due to price reductions in electric meters and delivery of distribution orders, while overseas distribution shows significant growth potential [8] - The company has revised down its net profit forecasts for 2025-2027 due to domestic challenges, but expects improvement in domestic profitability and strong overseas demand [8] Financial Performance Summary - Total revenue for 2023 is projected at 11,463 million yuan, with a year-on-year growth of 25.99% [1] - Net profit attributable to shareholders for 2023 is expected to be 1,904 million yuan, reflecting a year-on-year increase of 100.79% [1] - The latest diluted EPS for 2023 is estimated at 1.35 yuan per share [1] - The company anticipates total revenue of 16,063 million yuan in 2025, with a year-on-year growth of 10.02% [1] - The net profit attributable to shareholders for 2025 is projected to be 1,842 million yuan, indicating a year-on-year decrease of 18.49% [1] - The P/E ratio for 2025 is expected to be 17.53 [1] Market Data Summary - The closing price of the stock is 22.97 yuan, with a market capitalization of approximately 32,277.66 million yuan [5] - The stock has a price-to-book ratio of 2.60 [5] - The company has a total of 1,405.21 million shares outstanding [6] Operational Insights - The company has experienced a decline in gross margin due to significant price drops in electric meters, with a gross margin of 28.5% in Q1-3 2025, down 7.8 percentage points year-on-year [8] - The company is expanding its overseas distribution business, with a 125% year-on-year increase in overseas distribution orders as of September [8] - Cost control measures have been effective, with operating expenses decreasing by 5.8% year-on-year in Q1-3 2025 [8]